Sammy Corwin
Analyst
William Blair
Equibles does not estimate personal net worth.
About Sammy Corwin
Sammy Corwin is recorded as Analyst at William Blair. Sammy Corwin has spoken on 6 earnings calls across 4 companies, most recently for Ultragenyx Pharmaceutical Inc. on February 12, 2026. Those appearances were for Krystal Biotech, Inc. (KRYS), Zevra Therapeutics, Inc. (ZVRA), Ultragenyx Pharmaceutical Inc. (RARE) and Sarepta Therapeutics, Inc. (SRPT). The companies whose calls Sammy Corwin spoke on are classified in the Healthcare sector.
Sammy Corwin on recent calls
“I guess I was curious I'm curious what you're modeling for the potential sale of the priority review vouchers internally and if the recent renewal of the rare PDF disease PVR legislation changed those assumptions at all, and then just how much a change in price could impact your path to profitability in 2027.”
“Can we expect some guidance or full year revenue guidance for Vyjuvec early next year?”
“Given the turnover at FDA, you know, I understand that you had written guidance previously from the head of neuro, but I guess when was the last time you interacted with a division regarding the ESSENCE trial?”
“I was curious how many unique MyPipa prescribers there are now and how that's grown over the last quarter and if you are approaching prescriber saturation.”
“I have another couple questions about the upcoming European launches. I know previously you mentioned that there might be a dynamic of onboarding patients based on their need to get treated in a physician office first.”
Affiliation history
-
William Blair
Analyst
Transcript header (unverified)
Current